MS
CLDX icon

Maven Securities’s Celldex Therapeutics CLDX Stock Holding History

Maven Securities’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,492
Closed -$620K – 1095
2021
Q1 		$620K Sell
28,492
-33,684
-54% -$773K 0.03% 564
2020
Q4 		$1.11M Buy
+62,176
New +$1.12M 0.11% 220

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Maven Securities's CLDX Position: Q2 2021 in Review

Maven Securities sold out of Celldex Therapeutics (CLDX) in Q2 2021, closing a stake of 28,492 shares — an estimated $620K sold.

Maven Securities first reported a position in CLDX in Q4 2020 and held it in 2 quarters. The position peaked at $1.11M in Q4 2020. 131 funds tracked by Wall St. Rank hold CLDX as of Q2 2021.

  • Maven Securities reported no remaining Celldex Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 28,492 Celldex Therapeutics shares in Q2 2021, an estimated $620K.
  • Maven Securities first reported a position in Celldex Therapeutics in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Celldex Therapeutics position peaked at $1.11M in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.